PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have
metastatic neuroendocrine tumors.